23.09.2020 • News

OQ Chemicals Licenses Technologies to Duqm

OQ Chemicals – formerly Oxea – has agreed to license its proprietary technology for the production of ethylene and propylene derivatives to Oman’s Duqm Refinery and Petrochemicals Industries Company (DRPIC).

A joint venture between Oman Oil and Kuwait International Oil, DRPIC is planning a grassroots petrochemical complex at Duqm and has so far awarded 12 license packages to international technology providers.

Earlier this month, LyondellBasell announced it had been chosen to license its Spheripol PP and Hostalen HDPE technologies for plants at the proposed complex.

The contract with OQ Chemicals covers five plants to manufacture propanol, butyraldehyde, neopentyl glycol, 2-ethylhexanol (2-EH) and 2-EH acid. OQ Chemicals will supply a process design package and support contractors during the design and construction phases, along with providing various other services that include operational support, maintenance, training and ongoing process optimization.

OQ Chemicals chief operating officer Oliver Borgmeier said the company is applying the latest technologies at Duqm that it has developed for its own production plants in Bay City, Texas, USA, and Oberhausen, Germany.

Part of Oman Oil since 2013, Germany’s Oxea changed its name to OQ Chemicals in May this year, marking its final integration into Oman’s new petrochemicals and energy giant OQ.

 

Author: Elaine Burridge, Freelance Journalist

OQ Chemicals is to license its technology for the production of ethylene and...
OQ Chemicals is to license its technology for the production of ethylene and propylene derivatives to Oman’s Duqm Refinery and Petrochemicals Industries Company. The contract covers five plants for propanol, butyraldehyde, neopentyl glycol, 2-ethylhexanol (2-EH) and 2-EH acid. (c) OQ

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read